Moderna cut R&D spending by about 31% last year, citing the wind-down of major phase 3 respiratory trials.
Longevity News
Messenger RNA specialist Moderna's R&D spend sunk by nearly a third last year, a drop attributed in part to the wind-...
Source: FierceBiotech - Biotech • Published: 20 Feb 2026, 04:51
Continue exploring
Related longevity signals
Fight Aging!Bacterial Lipoic Acid Protein Ligase A Improves Mammalian Mitochondrial Function and HealthThis article previews research on using a bacterial enzyme to boost mitochondrial protein modification and overall cellular energy, framed as a potential metabolic-enhancing therapy. It invites readers curious about cross-species gene therapy approaches aimed at improving healthspan and age-related function.Nature - BiotechnologySEQURNA enhances FLASH-seq gene detection while eliminating DTT dependenceSEQURNA-focused methods article presenting a comparative benchmark of a synthetic thermostable RNase inhibitor for improved single-cell, full-length RNA-seq workflows.Longevity TechnologyClaremedica’s digital test finds 90% of new dementia cases earlyA report on a primary care group’s adoption of a digital cognitive assessment and what readers will learn about its implementation and uptake.Longevity TechnologyRetro Biosciences expands early trial for drug targeting Alzheimer’s, Parkinson’sA short news article about an early-stage clinical trial expansion testing higher doses of a candidate neurodegenerative drug, outlining safety and dosing goals and what readers can expect to learn.